Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat plus Cerezyme in adult and pediatric Gaucher disease type 3
2020-003120-17Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venglustat in Gaucher disease type 3, sponsored by Sanofi. Primary endpoint: Change in modified SARA total score at Week 52. Started Feb 2021; status: terminated.
02
Drugs
venglustat
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on 2020-003120-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003120-17.